References

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

10.1073/pnas.1004594107 · 2010 · External reference

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

10.1016/s1470-2045(13)70513-8 · 2014 · External reference

Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

10.1056/nejmoa1509388 · 2015 · External reference

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

10.1182/blood-2017-10-810044 · 2018 · External reference

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

10.1200/jco.2012.42.7906 · 2013 · External reference

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

10.1056/nejmoa1215637 · 2013 · External reference

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

10.1056/nejmoa1400376 · 2014 · External reference

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

10.1016/s1470-2045(16)30212-1 · 2016 · External reference

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

10.1182/blood-2018-08-870238 · 2019 · External reference

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

10.1182/blood.2019003570 · 2020 · External reference

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

10.3324/haematol.2017.182907 · 2018 · External reference

Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized trials

10.1097/md.0000000000016915 · 2019 · External reference

Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis

10.1371/journal.pone.0211228 · 2019 · External reference

Adverse events in clinical trials of ibrutinib and acalabrutinib for B-cell lymphoproliferative disorders: a systematic review and network meta-analysis

10.1182/blood-2020-137062 · 2020 · External reference

Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: focus on hypertension and cardiovascular toxicity

10.1002/cncr.34787 · 2023 · External reference

Ibrutinib resistance in chronic lymphocytic leukemia

10.1056/nejmc1402716 · 2014 · External reference

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

10.1182/blood-2015-02-626846 · 2015 · External reference

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

2016 · External reference

BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia

10.1200/jco.2016.70.2282 · 2017 · External reference

Cardiovascular toxicities associated with ibrutinib

10.1016/j.jacc.2019.07.056 · 2019 · External reference

Real-life insight into ibrutinib cardiovascular events: defining the loose ends

10.1016/j.jacc.2019.07.057 · 2019 · External reference

Data mining and safety analysis of BTK inhibitors: a pharmacovigilance investigation based on the FAERS database

10.3389/fphar.2022.995522 · 2022 · External reference

Cardiotoxicity of BTK inhibitors: ibrutinib and beyond

10.1080/17474086.2022.2067526 · 2022 · External reference

Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology state-of-the-art review

10.1016/j.jaccao.2023.09.002 · 2023 · External reference

Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia

10.1056/nejmoa1513257 · 2016 · External reference

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

10.1016/s1470-2045(16)30019-5 · 2016 · External reference

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

10.1016/s1470-2045(17)30909-9 · 2018 · External reference

Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia

10.1182/hematology.2020000120 · 2020 · External reference

How I manage CLL with venetoclax-based treatments

10.1182/blood.2019002841 · 2020 · External reference

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

10.1182/blood-2017-06-788133 · 2018 · External reference

Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study

10.1200/jco.18.01580 · 2019 · External reference

Four-year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)

10.1182/blood-2019-123930 · 2019 · External reference

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

10.1182/bloodadvances.2019000864 · 2020 · External reference

Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications

10.1016/j.hoc.2013.01.002 · 2013 · External reference

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

10.1182/blood-2009-06-225326 · 2009 · External reference

Proliferative signals in chronic lymphocytic leukemia; what are we missing?

10.3389/fonc.2020.592205 · 2020 · External reference

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

10.1182/blood.2019004326 · 2020 · External reference

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL

10.1038/s41418-020-00692-w · 2021 · External reference

IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells

10.1182/blood-2012-11-467670 · 2013 · External reference

Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering

10.1038/onc.2010.248 · 2010 · External reference

Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity

10.1182/blood-2006-05-021683 · 2006 · External reference

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

10.1038/s41375-023-01898-w · 2023 · External reference

Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors

2015 · External reference

BCL2 and miR-15/16: from gene discovery to treatment

10.1038/cdd.2017.159 · 2018 · External reference

BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia

10.1038/leu.2015.316 · 2016 · External reference

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

10.1182/bloodadvances.2020003944 · 2021 · External reference

Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia

10.1038/leu.2017.32 · 2017 · External reference

Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia

10.1158/1078-0432.ccr-14-2809 · 2015 · External reference

Noncatalytic Bruton's tyrosine kinase activates PLCγ(2) variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells

10.1074/jbc.ra119.011946 · 2020 · External reference

In BTK, phosphorylated Y223 in the SH3 domain mirrors catalytic activity, but does not influence biological function

10.1182/bloodadvances.2024012706 · 2024 · External reference

BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma

10.1016/j.jbc.2022.102555 · 2022 · External reference

Function of Bruton’s tyrosine kinase during B cell development is partially independent of its catalytic activity 1

10.4049/jimmunol.171.11.5988 · 2003 · External reference

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

10.1182/bloodadvances.2022008325 · 2022 · External reference

Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase Inhibitors

10.1056/nejmoa2114110 · 2022 · External reference

Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK

10.1126/scisignal.abg5216 · 2022 · External reference

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

10.1126/science.adi5798 · 2024 · External reference

Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes

10.1038/leu.2016.129 · 2016 · External reference

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia

10.1182/bloodadvances.2021004861 · 2021 · External reference

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication

10.1038/s41408-021-00429-z · 2021 · External reference

Ibrutinib and venetoclax for first-line treatment of CLL

10.1056/nejmoa1900574 · 2019 · External reference

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial

10.1001/jamaoncol.2021.1649 · 2021 · External reference

Combined ibrutinib and venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL): 5-year follow-up data

10.1182/blood-2023-189711 · 2023 · External reference

Combined ibrutinib and venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) [abstract]

10.1182/blood-2019-131732 · 2019 · External reference

Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): results from the MRD cohort of the phase 2 CAPTIVATE study [abstract]

10.1182/blood-2019-121424 · 2019 · External reference

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study

10.1200/jco.21.00807 · 2021 · External reference

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

10.1182/blood.2021014488 · 2022 · External reference

Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study

10.1200/jco.2023.41.16_suppl.7535 · 2023 · External reference

Ghia P Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): up to 5 years of follow-up from the FD cohort of the phase 2 CAPTIVATE study

2023 · External reference

Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study

10.1200/jco.19.00894 · 2019 · External reference

MRD4 eradication at 6 months and early clearance of MRD with combination of ibrutinib plus venetoclax results in sustained clinical and MRD responses: exploratory analysis of the blood cancer UK TAP clarity study

10.1182/blood-2022-166700 · 2022 · External reference

Continued long term responses to ibrutinib + venetoclax treatment for relapsed/refractory CLL in the blood cancer UK TAP clarity trial

10.1182/blood-2020-136960 · 2020 · External reference

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

10.1016/s1470-2045(23)00144-4 · 2023 · External reference

Chronic lymphocytic leukemia therapy guided by measurable residual disease

10.1056/nejmoa2310063 · 2024 · External reference

The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial

10.1097/01.hs9.0000843472.57904.29 · 2022 · External reference

Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI FLAIR study

10.1182/blood-2023-178298 · 2023 · External reference

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

10.1016/s1470-2045(23)00452-7 · 2023 · External reference

Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities

10.1056/evidoa2200006 · 2022 · External reference

10.1182/blood-2023-187128

10.1182/blood-2023-187128 · 2023 · External reference

A CAPTIVATEing analysis for higher-risk CLL

10.1158/1078-0432.ccr-23-0807 · 2023 · External reference

A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia

10.1182/blood-2018-06-860593 · 2018 · External reference

Ibrutinib dose modifications in the management of CLL

10.1186/s13045-020-00870-w · 2020 · External reference

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study

10.1182/bloodadvances.2023010236 · 2023 · External reference

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies

10.1002/jha2.427 · 2022 · External reference

Effective tumor debulking with ibrutinib before initiation of venetoclax: results from the CAPTIVATE minimal residual disease and fixed-duration cohorts

10.1158/1078-0432.ccr-22-0504 · 2022 · External reference

Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax

10.1158/1078-0432.ccr-22-3934 · 2024 · External reference

Overcoming resistance in chronic lymphocytic leukemia—maybe less is more?

10.1158/1078-0432.ccr-23-2872 · 2024 · External reference

10.1182/blood-2023-179541

10.1182/blood-2023-179541 · 2023 · External reference

Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy

10.1182/blood.2023019706 · 2024 · External reference

Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy

10.1158/1078-0432.ccr-21-4037 · 2022 · External reference

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

10.1186/s13045-021-01188-x · 2021 · External reference

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

2023 · External reference

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

10.1182/blood.2023022420 · 2024 · External reference

Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma [abstract]

10.1007/s00277-021-04535-7 · 2021 · External reference

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

10.1182/blood.2023020158 · 2023 · External reference